CStone Pharmaceuticals: Sugli monoclonal antibody for third-line non-small cell lung cancer receives approval from the UK MHRA

Jiangsu Hengrui Medicine announced on February 23 that the new indication application for Sugli monoclonal antibody has been approved by the UK MHRA for monotherapy in the treatment of adult patients with unresectable stage III NSCLC who have tumor cell PD-L1 expression ≥1%, no sensitive epidermal growth factor receptor (EGFR) mutations or ALK, ROS1 gene alterations, and no disease progression after platinum-based chemoradiotherapy (CRT).